Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYNT-202
- Development stage
- Preclinical
- Lead developer
- Syntis Bio
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral
01
Overview
SYNT-202 is an orally administered, gastrointestinal-stable methionine-gamma-lyase enzyme therapy being developed for the treatment of classical homocystinuria. It is designed to metabolize and eliminate methionine in the digestive tract, thereby reducing circulating homocysteine levels. The drug leverages Syntis Bio’s proprietary SYNT (Synthetic Tissue-lining) technology platform to sustain local enzyme activity in the small intestine for extended periods, improving therapeutic performance and reducing dosing frequency. SYNT-202 is engineered for stability and enhanced intestinal residence time using this platform. The therapy aims to provide a disease-modifying approach for homocystinuria—a rare metabolic disorder with significant unmet medical need—by continuously breaking down harmful amino acids in the gut[1][2][5][8].
- Other names
- SYNT 202SYNT202SYNT-202CDX-65122CDX65122CDX 65122
02
Targets
MGL (Methionine gamma-lyase)
Beyond the preview
Go deeper on SYNT-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYNT-202.